Vascular Biogenics Ltd. Культура компании

Prof. Dror Harats, MD has been the Chief Executive Officer of Vascular Biogenics Ltd., since 2000. Prof. Harats founded VBL in 2000 based on over 20 years of research in Atherosclerosis, Vascular Biology and Lipid Metabolism. Prof. Harats is the Chairman of Bert W Strassburger Lipid Centre Review Board and its Director at Chaim Sheba Medical Centre - Tel Hashomer. He has been a Director of Vascular Biogenics Ltd. since January 2001. He consulted to major Pharmaceutical Companies. He is also a Professor of Medicine in the Departments of Internal Medicine and Biochemistry at the Sackler Faculty of Medicine of Tel-Aviv University. Prof. Harats received MD from Hadassah Medical School at the Hebrew University of Jerusalem, Israel and has carried out Post-Doctoral work at University of California, San Francisco.

Mr. Amos Ron has been the Chief Financial Officer of Vascular Biogenics Ltd., since May 2011 and serves as its Principal Accounting Officer and Company Secretary. Mr. Ron serves as Director General of Israel Ports Authority. Mr. Ron served as Chief Financial Officer of Atlantium Technologies Ltd. since August 2008 until April 2011. Prior to joining Atlantium, he served as Chief Financial Officer and Chief Operating Officer of Medical Compression Systems (D.B.N), an Israeli company traded on the TASE. He served as the Chief Executive Officer of Israel Ports Company Ltd. Mr. Ron has more than 20 years experience at Israeli and multinational companies and has held Chief Financial Officer, Chief Operating Officer, Site Director, Supply Chain Management and Product Marketing positions in the Medical Device, Bio-Pharm, Chemical and Textile industries. He has led efforts such as a successful IPO on the TASE, ISO 9002 implementation, large scale CAPEX and IT projects, cost reduction, capacity extension through efficiency increases, lead-time reduction, quality improvement projects and more. Mr. Ron worked as the Chairman, Metro-Net Ltd. Group; Director General, Ministry of Energy for Infrastructure from 1994 to 1995 and Vice President, Marketing & Customer Service, Bezeq The Israel Telecommunication Corp. He served as a Director at Dor Alon Energy In Israel (1988) Ltd. since December 12, 2005. He has a B.A. degree in Economics & Psychology, Haifa University in 1978. Mr. Ron holds an M.Sc. (Honors) in Chemical Technology Management from Hebrew University, a B.Sc. in Business Administration, Empire State College (Jerusalem Branch) and a B.Sc. in Chemistry from Hebrew University.

Dr. Erez Feige, Ph.D., M.B.A., has been a Vice President of Business Operations at Vascular Biogenics Ltd. since January 2014 and served as its Director of Business Development from 2012 to 2014. Dr. Feige joined VBL in 2006. He has extensive experience in cancer and immune-inflammatory research as well as in biochemistry and molecular biology. He holds a B.Sc., and M.B.A. and Ph.D. from Bar-Ilan University, Israel and completed a post-doctoral fellowship at the Dana-Farber Cancer institute and Harvard Medical School in Boston, Mass., U.S.

Dr. Corinne Epperly, MD, MPH, has been U.S. Chief Operating Officer at Vascular Biogenics Ltd. since June 15, 2017. Dr. Epperly is an oncology expert with industry background in drug development, strategy, commercialization and operations. Dr. Epperly joined VBL after seven years at Bristol-Myers Squibb (BMS), where she delivered results across diverse roles spanning marketing, M&A, strategic operations and medical strategy. Most recently, she was involved in leading the preparation for the commercial launches of OPDIVO?? (nivolumab) in both hepatocellular carcinoma and in glioblastoma. While at BMS, she led U.S. immuno-oncology safety management, advancing the safety strategy with oncology stakeholders. Dr. Epperly also served as the Global Mergers & Acquisitions Lead in the Strategic Transactions Group at BMS. Prior to joining BMS, she was a member of the Global Healthcare Investment Research team at Goldman Sachs, based in London, where she helped relaunch the European Pharmaceutical and Biotech Team. She served as a Research Analyst at Goldman Sachs Group Inc., Research Division from July 2009 to December 2010. Dr. Epperly holds a dual graduate degree, an M.D. and an MPH from the University of North Carolina at Chapel Hill. She completed her medical training at the University of North Carolina Hospitals with the Department of Pediatrics. She earned a Distinguished B.A. from the University of Virginia where she studied biochemistry and biology. Dr. Epperly conducted biomedical research in Experimental Immunology on checkpoint inhibition and tumor suppressor genes in the National Cancer Institute, National Institutes of Health. She is a Medicin?? Doctor.

Corinne Epperly serves as the US Chief Operating Officer for Vascular Biogenics Ltd. (also known as VBL Therapeutics). Corinne started at Vascular Biogenics Ltd. (also known as VBL Therapeutics) in June of 2017. Corinne is based in the Greater New York City Area.